Slingshot members are tracking this event:

Final Decision Expected from European Commission in ~60 Days on Novarits' (NVS) Arzerra in Adult Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Final Decision, European Commission, Chmp, Arzerra, Chronic Lymphocytic Leukemia, Cll